Unaudited financial results for q.e. 30-06-2025 are enclosed herewith
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kwality Pharmaceuticals reported a strong Q1 FY26 with consolidated revenue from operations rising about 39% year-on-year to Rs. 111.5 crore from Rs. 80.1 crore in Q1 FY25, driven by higher sales of registered products in international markets. EBITDA grew around 39% to Rs. 24.6 crore while EBITDA margin held steady at roughly 22%, showing operating efficiency even as the business scaled. Net profit (PAT) rose about 43% to Rs. 11.9 crore from Rs. 8.3 crore, with basic EPS at Rs. 11.49 versus Rs. 8.04. The company also highlighted completion of a Zimbabwe regulatory audit, multiple new product registrations, an upcoming EU-GMP audit in October, and WHO-GMP inspection preparations for its biologics facility. Management reiterated its Rs. 500 crore revenue target for FY26.
A clean unmodified auditor review combined with strong double-digit revenue and profit growth in line with the management's FY26 targets is positive for shareholders and likely supports the stock in the near term. Key watch-items are execution on the EU-GMP and biologics milestones and continued margin stability.